{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-017841","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.460466+00:00","generated_at":"2026-06-18T11:58:30.826854+00:00","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Unicycive raises up to $130M in private placement led by Vivo Capital for Renazorb launch","bullets":["$30M upfront from Series A-1 Convertible Preferred Stock; up to $100M additional via milestone-linked warrants.","Tranche A warrants ($25M) exercisable upon FDA approval of Renazorb; Tranche B ($25M) upon TDAPA approval; Tranche C ($50M) after four quarters of commercial sales.","Gaurav Aggarwal, MD (Vivo Capital) appointed to Board of Directors effective at closing.","Company to adopt dividend policy paying at least 75% of annual net cash flow from operations to all stockholders post-approval and commercial sales.","Proceeds to support NDA submission for Renazorb (hyperphosphatemia) and potential U.S. commercial launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-017841","json":"https://secwatch.observer/filing/0001213900-23-017841.json","markdown":"https://secwatch.observer/filing/0001213900-23-017841.md","text":"https://secwatch.observer/filing/0001213900-23-017841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/ea174702-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:58:30.826854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae1aeb10fa","claim":"Gaurav Aggarwal was appointed as Director at Unicycive Therapeutics, Inc..","evidence_excerpt":"effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"521bc3f085a64eb84f17a9e2f3c5032d65caeb26","claim":"Unicycive Therapeutics, Inc.: Gaurav Aggarwal, MD was appointed to the Board of Directors effective upon closing of the offering, with standard non-employee director compensation and indemnification (effective 2023-03-06).","evidence_excerpt":"Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Effective","value":"2023-03-06"}],"fact_type":"governance_change"},{"claim_id":"d884910403650f70cede42d21906b5a76ff79fbe","claim":"Unicycive Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at $30 million (effective 2023-03-03).","evidence_excerpt":"On March 3, 2023, Unicycive Therapeutics , Inc. (the \" Company \") entered into a securities purchase agreement (the \" Purchase Agreement \") with certain accredited investors (the \" Investors \"), pursuant to which the Company agreed to issue and sell, in a private placement (the \" Offering \"), 30,190 shares of Series A-1 Convertible Preferred Stock, par value $0.001 per share (the \" Series A-1 Preferred Stock \"), for an aggregate offering price of $30 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2023-03-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}